Shares Outstanding Shares Outstanding n/a Close	46.32M
Shares Change (YoY) Shares Change (YoY) n/a Close	-10.45%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.16%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	84.32%
Shares Floating Shares Floating n/a Close	41.55M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	139
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.02%

Short Selling Information

The latest short interest is 4.35M, so 9.4% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	4.35M
Short % of Shares Out Short % of Shares Out n/a Close	9.4%
Short % of Float Short % of Float n/a Close	9.78%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	10.97

Valuation Ratios

The PE ratio is -1.87 and the forward PE ratio is -1.05. 4D Molecular Therapeutics's PEG ratio is -0.12.

PE Ratio PE Ratio n/a Close	-1.87
Forward PE Forward PE n/a Close	-1.05
PS Ratio PS Ratio n/a Close	8120.72
Forward PS Forward PS n/a Close	1.8
PB Ratio PB Ratio n/a Close	0.59
P/FCF Ratio P/FCF Ratio n/a Close	-2.17
PEG Ratio PEG Ratio n/a Close	-0.12

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 14.92, with a Debt / Equity ratio of 0.05.

Current Ratio Current Ratio n/a Close	14.92
Quick Ratio Quick Ratio n/a Close	14.92
Debt / Equity Debt / Equity n/a Close	0.05
Debt / EBITDA Debt / EBITDA n/a Close	-0.13
Debt / FCF Debt / FCF n/a Close	-0.18
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$163
Profits Per Employee Profits Per Employee n/a Close	$-708,669.6
Employee Count Employee Count n/a Close	227
Asset Turnover Asset Turnover n/a Close	0
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -80.55% in the last 52 weeks. The beta is 2.83, so 4D Molecular Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	2.83
52-Week Price Change 52-Week Price Change n/a Close	-80.55%
50-Day Moving Average 50-Day Moving Average n/a Close	3.65
200-Day Moving Average 200-Day Moving Average n/a Close	6.08
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	52.66
Average Volume (20 Days) Average Volume (20 Days) n/a Close	576,916

Income Statement

In the last 12 months, 4D Molecular Therapeutics had revenue of 37K and earned -160.87M in profits. Earnings per share was -2.98.

Revenue Revenue n/a Close	37K
Gross Profit Gross Profit n/a Close	37K
Operating Income Operating Income n/a Close	-187.84M
Net Income Net Income n/a Close	-160.87M
EBITDA EBITDA n/a Close	-187.84M
EBIT EBIT n/a Close	-187.84M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-2.98

Full Income Statement

Balance Sheet

The company has 149.34M in cash and 24.61M in debt, giving a net cash position of 124.73M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	149.34M
Total Debt Total Debt n/a Close	24.61M
Net Cash Net Cash n/a Close	124.73M
Retained Earnings Retained Earnings n/a Close	-576.2M
Total Assets Total Assets n/a Close	515.73M
Working Capital Working Capital n/a Close	305.67M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -134.59M and capital expenditures -3.79M, giving a free cash flow of -138.37M.

Operating Cash Flow Operating Cash Flow n/a Close	-134.59M
Capital Expenditures Capital Expenditures n/a Close	-3.79M
Free Cash Flow Free Cash Flow n/a Close	-138.37M
FCF Per Share FCF Per Share n/a Close	-2.57

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.

Gross Margin Gross Margin n/a Close	100%
Operating Margin Operating Margin n/a Close	-507678.38%
Pretax Margin Pretax Margin n/a Close	-434778.38%
Profit Margin Profit Margin n/a Close	-434778.38%
EBITDA Margin EBITDA Margin n/a Close	-507678.38%
EBIT Margin EBIT Margin n/a Close	-507678.38%
FCF Margin FCF Margin n/a Close	-373975.68%

Dividends & Yields

FDMT does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for FDMT is $37, which is 809.1% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$37
Price Target Difference Price Target Difference n/a Close	809.1%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Scores

Altman Z-Score Altman Z-Score n/a Close	-0.19
Piotroski F-Score Piotroski F-Score n/a Close	2